Menu
Search
|

Menu

Close
X

CRISPR Therapeutics AG CRSP.OQ (NASDAQ Stock Exchange Global Market)

49.40 USD
-- (--)
As of Sep 18
Previous Close 49.40
Open --
Volume --
3m Avg Volume 136,323
Today’s High --
Today’s Low --
52 Week High 53.90
52 Week Low 22.23
Shares Outstanding (mil) 52.91
Market Capitalization (mil) 2,715.34
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.38 Mean rating from 16 analysts

KEY STATS

Revenue (mm, USD)
FY19
1
FY18
3
FY17
41
FY16
5
EPS (USD)
FY19
-1.939
FY18
-3.426
FY17
-1.713
FY16
0.382
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.85
Price to Sales (TTM)
vs sector
2,050.86
7.90
Price to Book (MRQ)
vs sector
7.47
4.38
Price to Cash Flow (TTM)
vs sector
--
23.70
Total Debt to Equity (MRQ)
vs sector
0.00
17.64
LT Debt to Equity (MRQ)
vs sector
0.00
12.61
Return on Investment (TTM)
vs sector
-50.26
12.69
Return on Equity (TTM)
vs sector
-63.34
17.13

EXECUTIVE LEADERSHIP

Rodger Novak
Chairman of the Board of Directors, President, Founder, Since 2017
Salary: $356,242.00
Bonus: $118,424.00
Samarth Kulkarni
Chief Executive Officer, Director, Since 2018
Salary: $145,833.00
Bonus: $43,750.00
Kala Subramanian
Senior Vice President - Strategic Development and Operations, Since 2016
Salary: --
Bonus: --
Megan Wherry Menner
Senior Vice President of Human Resources, Since
Salary: --
Bonus: --
Sven Lundberg
Chief Scientific Officer, Since 2015
Salary: $302,605.00
Bonus: $90,928.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Baarerstrasse 14
ZUG   ZUG   6300

Phone: +4141.5613277

CRISPR Therapeutics AG is a Switzerland-based gene-editing company. It focuses on the development of transformative gene-based medicines for serious diseases. The Company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform, which allows for precise directed changes to genomic deoxyribonucleic acid (DNA). The Company has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine and rare diseases. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The Company has business operations in London and the United Kingdom, as well as research and development operations in the United States.

SPONSORED STORIES